TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab

Rheumatology (United Kingdom)

Volumn 53, Issue 1, 2014, Pages 198-200

  Ferrero, Elisabetta ^a   Belloni, Daniela ^a   Corti, Angelo ^a   Doglioni, Claudio ^a,b   Dagna, Lorenzo ^a,b   Ferrarini, Marina ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA;

ADULT; BONE PAIN; BONE SCINTISCANNING; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DIABETES INSIPIDUS; DRUG MEGADOSE; DRUG WITHDRAWAL; ERDHEIM CHESTER DISEASE; FOLLOW UP; HUMAN; HYDRONEPHROSIS; IN VITRO STUDY; LETTER; MALE; MIDDLE AGED; PERICARDIAL DRAIN; PERICARDIAL EFFUSION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETROPERITONEAL DISEASE; UMBILICAL VEIN ENDOTHELIAL CELL; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ERDHEIM-CHESTER DISEASE; HUMANS; MALE; MIDDLE AGED; PERICARDIAL EFFUSION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890930276     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket246     Document Type: Letter

References (10)

1. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53-9.
2. Haroche J, Amoura Z, Dion E et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine 2004;83:371-92.
3. Haroche J, Amoura Z, Trad SG et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006;54:3330-6.
4. Stoppacciaro A, Ferrarini M, Salmaggi C et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006;54:4018-22.
5. Dagna L, Girlanda S, Langheim S et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology 2010;49:1203-6.
6. Arnaud L, Gorochov G, Charlotte F et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011;117:2783-90.
7. Dagna L, Corti A, Langheim S et al. Tumor necrosis factor a as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012;30: e286-90.
8. Ferrero E, Scabini S, Magni E et al. Chromogranin A protects vessels against tumor necrosis factor a-induced vascular leakage. FASEB J 2004;18:554-6.
9. Karatolios K, Moosdorf R, Maisch B et al. Cytokines in pericardial effusion of patients with inflammatory pericardial disease. Mediators Inflamm 2012;2012:382082.
10. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82.